The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme

References

• Kurochkin IV. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 2001; 26:421 - 425
   PubMed Web of Science ®Google Scholar
• Morelli L, Llovera RE, Alonso LG, Frangione B, de Prat Gay G, Ghiso J, Castaño EM. Biochem Biophys Res Commun 2005; 332:808 - 816
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100:4162 - 4167
   PubMed Web of Science ®Google Scholar
• Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL. Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003; 100:6221 - 6226
   PubMed Web of Science ®Google Scholar
• Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 2007; 72:217 - 233
   PubMedGoogle Scholar
• Pérez A, Morelli L, Cresto JC, Castaño EM. Degradation of soluble amyloid β-peptides 1–40, 1–42, and the Dutch variant 1–40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000; 25:247 - 255
   PubMed Web of Science ®Google Scholar
• Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, Castaéo EM. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid β vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem 2004; 279:56004 - 56013
   PubMed Web of Science ®Google Scholar
• Shinall H, Song ES, Hersh LB. Susceptibility of amyloid β peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 2005; 44:15345 - 15350
   PubMed Web of Science ®Google Scholar
• Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol Aging 2005; 26:645 - 654
   PubMed Web of Science ®Google Scholar
• Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007; 282:7825 - 7832
   PubMed Web of Science ®Google Scholar
• Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006; 443:870 - 874
   PubMed Web of Science ®Google Scholar
• Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem 2007; 282:25453 - 25463
   PubMed Web of Science ®Google Scholar
• Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castaño EM. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid β peptide: Implications for Alzheimer's disease pathogenesis. J Biol Chem 2008; 17039 - 17048
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E, high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:1977 - 1981
   PubMed Web of Science ®Google Scholar
• Munson GW, Roher AE, Kuo YM, Gilligan SM, Reardon CA, Getz GS, LaDu MJ. SDS-stable complex formation between native apolipoprotein E3 and β-amyloid peptides. Biochemistry 2000; 39:16119 - 16124
   PubMed Web of Science ®Google Scholar
• Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A β interaction. J Biol Chem 1995; 270:7563 - 7567
   PubMed Web of Science ®Google Scholar
• Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S. α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 1998; 95:3275 - 3280
   PubMed Web of Science ®Google Scholar
• Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldgaber D. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994; 91:8368 - 8372
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Ray I, Chauhan A, Wisniewski HM. Binding of gelsolin, a secretory protein, to amyloid β-protein. Biochem Biophys Res Commun 1999; 258:241 - 246
   PubMed Web of Science ®Google Scholar
• Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-amyloid (1–42) binds to δ7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275:5626 - 5632
   PubMed Web of Science ®Google Scholar
• Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997; 389:689 - 695
   PubMed Web of Science ®Google Scholar
• Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304:448 - 452
   PubMed Web of Science ®Google Scholar
• Barondeau DP, Kassmann CJ, Tainer JA, Getzoff ED. Understanding GFP chromophore biosynthesis: controlling backbone cyclization and modifying post-translational chemistry. Biochemistry 2005; 44:1960 - 1970
   PubMed Web of Science ®Google Scholar
• O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279:17490 - 17499
   PubMed Web of Science ®Google Scholar
• Yan J, Fu X, Ge F, Zhang B, Yao J, Zhang H, Qian J, Tomozawa H, Naiki H, Sawashita J, Mori M, Higuchi K. Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 2007; 171:172 - 180
   PubMed Web of Science ®Google Scholar
• Hamel FG, Siford GL, Jones J, Duckworth WC. Intraendosomal degradation of transforming growth factor α. Mol Cell Endocrinol 1997; 126:185 - 192
   PubMed Web of Science ®Google Scholar
• Douglas PM, Treusch S, Ren HY, Halfmann R, Duennwald ML, Lindquist S, Cyr DM. Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci USA 2008; 105:7206 - 7211
   PubMed Web of Science ®Google Scholar
• Li Q, Ali MA, Cohen JI. Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell 2006; 127:305 - 316
   Google Scholar
• Gilden DH, Mahalingam R, Cohrs RJ, Kleinschmidt-DeMasters BK, Forghani B. The protean manifestations of varicella-zoster virus vasculopathy. J Neurovirol 2002; 2:75 - 79
   Web of Science ®Google Scholar
• Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 1986; 49:1221 - 1226
   PubMed Web of Science ®Google Scholar
• Li Q, Krogmann T, Ali MA, Tang WJ, Cohen JI. The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor. J Virol 2007; 81:8525 - 8532
   PubMed Web of Science ®Google Scholar
• Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 7:902 - 904
   Google Scholar
• Lesné S, Gabriel C, Nelson DA, White E, Mackenzie ET, Vivien D, Buisson A. Akt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicity. J Biol Chem 2005; 280:24941 - 24947
   PubMed Web of Science ®Google Scholar
• Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24:11120 - 11126
   PubMed Web of Science ®Google Scholar
• Egawa K, Nakashima N, Sharma PM, Maegawa H, Nagai Y, Kashiwagi A, Kikkawa R, Olefsky JM. Persistent activation of phosphatidylinositol 3-kinase causes insulin resistance due to accelerated insulin-induced insulin receptor substrate-1 degradation in 3T3-L1 adipocytes. Endocrinology 2000; 141:1930 - 1935
   PubMed Web of Science ®Google Scholar
• Peers C, Pearson HA, Boyle JP. Hypoxia and Alzheimer's disease. Essays Biochem 2007; 43:153 - 164
   PubMed Web of Science ®Google Scholar
• Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W. Hypoxia facilitates Alzheimer's disease pathogenesis by upregulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103:18727 - 18732
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang YW, Zhang X, Liu R, Zhang X, Hong S, Xia K, Xia J, Zhang Z, Xu H. Transcriptional regulation of APH-1A and increased γ-secretase cleavage of APP and Notch by HIF-1 and hypoxia. FASEB J 2006; 20:1275 - 1277
   PubMed Web of Science ®Google Scholar
• Malito E, Hulse RE, Tang WJ. Amyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase and neprilysin. Cell Mol Life Sci 2008; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Demaurex N. pH homeostasis of cellular organelles. News Physiol Sci 2002; 17:1 - 5
   Google Scholar